13F Holdings
中文EN

AZR Azora Therapeutics, Inc. (DE)

Pharmaceutical Preparations · Nasdaq · SEC CIK 1513525 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-1,397.4%
TTM EPS YoY76.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-855.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets22.4%
Debt / equity—
Current ratio4.43x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.13x
Accruals ratio-742.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$2.62M$3.23M$1.27M$1.95M$8.40M
SG&A expense$5.18M$5.06M$5.62M$8.91M$9.34M
Operating income-$7.80M-$8.28M-$6.89M-$10.86M-$19.29M
Pretax income-$7.98M-$13.20M-$7.00M-$10.80M-$19.52M
Income tax———-$502-$94,077
Net income-$7.98M-$13.20M-$5.12M-$12.73M-$19.42M
EPS (basic)-11.93-68.01-3.60-12.71-1.04
EPS (diluted)-11.93-68.01-3.60-12.71-1.04
Weighted avg. shares (diluted)668,630194,0591.42M1.00M18.59M
Balance sheet
Cash & equivalents$5.88M$3.75M$2.83M$4.00M$6.06M
Current assets$6.18M$4.06M$3.20M$4.78M$6.46M
PP&E, net———$50,424$58,149
Goodwill———$248,971$248,971
Intangibles$3,000$3,348$3,913$4,477$5,041
Total assets$6.67M$5.04M$4.74M$5.73M$7.47M
Current liabilities$1.40M$975,858$653,076$1.79M$2.72M
Total liabilities$1.40M$975,858$653,076$2.46M$3.97M
Shareholders' equity$5.28M$4.07M$4.08M$3.28M$3.51M
Shares outstanding1.11M258,8261.66M1.07M20.95M
Cash flow statement
Operating cash flow-$6.49M-$6.92M-$6.81M-$11.19M-$11.95M
Capital expenditure————$64,605
Free cash flow————-$12.01M
Investing cash flow$150,000—$1.50M—-$34,016
Financing cash flow$8.47M$7.85M$4.13M$9.13M$13.64M
Stock-based compensation$676,200$796,831$1.75M$3.37M$4.24M
Share buybacks——$1,661——

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.